Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND LEVONORGESTREL versus FEMTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND LEVONORGESTREL versus FEMTRACE.
ETHINYL ESTRADIOL AND LEVONORGESTREL vs FEMTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive; ethinyl estradiol provides estrogenic activity, levonorgestrel provides progestational activity, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
One tablet containing 0.02-0.05 mg ethinyl estradiol and 0.1-0.15 mg levonorgestrel orally once daily for 21 days, followed by 7 days of placebo or no tablets.
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal). Levonorgestrel: 18-30 hours (terminal). Clinical context: steady state achieved in 5-7 days; missed doses may require backup contraception.
Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use.
Urine (40% ethinyl estradiol metabolites, 40% levonorgestrel metabolites); feces (40% ethinyl estradiol, 20% levonorgestrel).
Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%).
Category D/X
Category C
Estrogen
Estrogen